{"id":67816,"date":"2026-06-09T23:30:51","date_gmt":"2026-06-09T15:30:51","guid":{"rendered":"https:\/\/flcube.com\/?p=67816"},"modified":"2026-06-09T23:30:52","modified_gmt":"2026-06-09T15:30:52","slug":"lepu-medical-receives-tga-approval-for-phase-i-trial-of-dual-targeting-sirna-mwx205-against-pcsk9-and-angptl3-in-australia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67816","title":{"rendered":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lepu Medical Technology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300003:SHE\">SHE: 300003<\/a>), a leading provider of cardiovascular disease solutions, announced today that Australia&#8217;s <strong>Therapeutic Goods Administration (TGA)<\/strong> has granted approval to initiate a <strong>Phase I clinical trial<\/strong> for its <strong>MWX205<\/strong>, a novel <strong>small interfering RNA (siRNA) drug<\/strong> simultaneously targeting <strong>PCSK9<\/strong> and <strong>ANGPTL3<\/strong> for the treatment of dyslipidemia.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>MWX205<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Lepu Medical Technology (SHE: 300003)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>Therapeutic Goods Administration (TGA), Australia<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase I clinical trial authorization<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Dual-targeting small interfering RNA (siRNA)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>PCSK9 and ANGPTL3<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-dual-lipid-regulation\" class=\"wp-block-heading\">Mechanism of Action \u2013 Dual Lipid Regulation<\/h2>\n\n\n\n<h3 id=\"h-pcsk9-inhibition-pathway\" class=\"wp-block-heading\">PCSK9 Inhibition Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Effect<\/strong>: Inhibits PCSK9 expression, increasing low-density lipoprotein receptors (LDLR) on hepatocyte surfaces<\/li>\n\n\n\n<li><strong>Primary Outcome<\/strong>: Potent reduction of low-density lipoprotein cholesterol (LDL-C) levels<\/li>\n\n\n\n<li><strong>Clinical Relevance<\/strong>: Addresses primary target for cardiovascular risk reduction<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-angptl3-inhibition-pathway\" class=\"wp-block-heading\">ANGPTL3 Inhibition Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Effect<\/strong>: Inhibits ANGPTL3 expression, modulating lipoprotein lipase (LPL) and hepatic lipase (HL) activity<\/li>\n\n\n\n<li><strong>Dual Benefits<\/strong>: Further reduces LDL-C while demonstrating excellent triglyceride (TG) and triglyceride-rich lipoprotein (TRL) lowering efficacy<\/li>\n\n\n\n<li><strong>Comprehensive Lipid Control<\/strong>: Addresses multiple atherogenic lipid parameters simultaneously<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-data-foundation\" class=\"wp-block-heading\">Preclinical Data Foundation<\/h2>\n\n\n\n<h3 id=\"h-target-inhibition-results\" class=\"wp-block-heading\">Target Inhibition Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Maximum Inhibition Rate<\/th><th>Duration of Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>PCSK9<\/strong><\/td><td>82.21%<\/td><td>Up to 12 weeks<\/td><\/tr><tr><td><strong>ANGPTL3<\/strong><\/td><td>94.41%<\/td><td>Up to 12 weeks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-lipid-profile-improvements\" class=\"wp-block-heading\">Lipid Profile Improvements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LDL-C Reduction<\/strong>: Significant decrease in low-density lipoprotein cholesterol<\/li>\n\n\n\n<li><strong>Triglyceride Reduction<\/strong>: Marked lowering of triglyceride levels<\/li>\n\n\n\n<li><strong>Total Cholesterol<\/strong>: Substantial reduction in total cholesterol (TC)<\/li>\n\n\n\n<li><strong>Study Duration<\/strong>: Effects sustained through 12-week study endpoint<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Leadership<\/strong>: Positions Lepu as pioneer in dual-targeting siRNA therapeutics for cardiovascular disease<\/li>\n\n\n\n<li><strong>Global Development<\/strong>: Australian trial serves as foundation for international regulatory filings<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success would validate Lepu&#8217;s siRNA technology platform for future pipeline candidates<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: Dual mechanism offers potential advantages over single-target lipid-lowering agents<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dyslipidemia Prevalence<\/strong>: Affects over 1 billion people globally with significant cardiovascular risk implications<\/li>\n\n\n\n<li><strong>siRNA Therapeutics<\/strong>: Emerging class with demonstrated durability and infrequent dosing requirements<\/li>\n\n\n\n<li><strong>PCSK9 Market<\/strong>: Established target with proven cardiovascular benefit but high treatment costs<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited options for patients requiring both LDL-C and triglyceride reduction<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and execution challenges in novel therapeutic development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u53cc\u9776\u70b9siRNA\u836f\u7269MWX205\u6ce8\u5c04\u6db2\u63d0\u4ea4\u6fb3\u6d32\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u5e76\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u53cc\u9776\u70b9siRNA\u836f\u7269MWX205\u6ce8\u5c04\u6db2\u63d0\u4ea4\u6fb3\u6d32\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u5e76\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-de25458c-7818-4f94-8646-7882a59a0d9b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u53cc\u9776\u70b9siRNA\u836f\u7269MWX205\u6ce8\u5c04\u6db2\u63d0\u4ea4\u6fb3\u6d32\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u5e76\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u53cc\u9776\u70b9siRNA\u836f\u7269MWX205\u6ce8\u5c04\u6db2\u63d0\u4ea4\u6fb3\u6d32\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u5e76\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u53cc\u9776\u70b9siRNA\u836f\u7269MWX205\u6ce8\u5c04\u6db2\u63d0\u4ea4\u6fb3\u6d32\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u5e76\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-de25458c-7818-4f94-8646-7882a59a0d9b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,374,64,864],"class_list":["post-67816","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-lepu-medical-technology","tag-rnai-aso","tag-she-300003"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia&#039;s Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67816\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia\" \/>\n<meta property=\"og:description\" content=\"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia&#039;s Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67816\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:30:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:30:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia\",\"datePublished\":\"2026-06-09T15:30:51+00:00\",\"dateModified\":\"2026-06-09T15:30:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Lepu Medical Technology\",\"RNAi \\\/ ASO\",\"SHE: 300003\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67816#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67816\",\"name\":\"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:30:51+00:00\",\"dateModified\":\"2026-06-09T15:30:52+00:00\",\"description\":\"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia's Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67816\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67816#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia's Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67816","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia","og_description":"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia's Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.","og_url":"https:\/\/flcube.com\/?p=67816","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:30:51+00:00","article_modified_time":"2026-06-09T15:30:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67816#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67816"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia","datePublished":"2026-06-09T15:30:51+00:00","dateModified":"2026-06-09T15:30:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67816"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Lepu Medical Technology","RNAi \/ ASO","SHE: 300003"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67816#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67816","url":"https:\/\/flcube.com\/?p=67816","name":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:30:51+00:00","dateModified":"2026-06-09T15:30:52+00:00","description":"Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that Australia's Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical trial for its MWX205, a novel small interfering RNA (siRNA) drug simultaneously targeting PCSK9 and ANGPTL3 for the treatment of dyslipidemia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67816#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67816"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67816#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67816"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67816\/revisions"}],"predecessor-version":[{"id":67819,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67816\/revisions\/67819"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}